Lynparza gets broader US ovarian cancer approval
11 May 2020 07:00 BST Lynparza approved in the US as 1st-line maintenance treatment with bevacizumab for HRD-positive advanced ovarian cancer Patients treated with Lynparza and bevacizumab lived without disease progression for 37.2 months vs. 17.7 months median for bevacizumab alone One in two women with advanced ovarian cancer has an HRD-positive tumour AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that Lynparza (olaparib) in combination with bevacizumab has been approved in the US for the